Logo for: LBB Specialties
Phase A INCI Name %W/W
Deionized Water Water 76.40
Sodium Metabisulfite Sodium Metabisulfite 0.05
Phase B INCI Name %W/W
1 Simulgel™ I-NS 100 Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Isohexadecane, Polysorbate 60 3.00
2 Neossance™ Squalane Squalane 7.50
2 Neossance™ Hemisqualane C13-15 Alkane 5.00
3 Lecinol S-10 Hydrogenated Lecithin 1.00
Phase C INCI Name %W/W
4 Mixed Tocopherols 95 Tocopherol 0.05
Phase D INCI Name %W/W
5 Diocide™ Caprylyl Glycol, Phenoxyethanol, Hexylene Glycol 1.00
Phase E INCI Name %W/W
5 Centersome® RL Water, Pentylene Glycol, Lecithin, Retinol, Polysorbate 20, Glycerin, Tocopherol, Ethanol, Potassium Phosphate, Sodium Hydroxide 2.00
6 ALPHA-ARBUTIN Alpha-Arbutin 2.00
7 Altheostem™ Propanediol, Water, Glycerin, Althaea Rosea Flower Extract, Xanthan Gum 2.00
1Manufactured by Seppic
2Manufactured by Aprinnova
3Manufactured by Nikkol
4Manufactured by dsm-firmenich
5Manufactured for LBB Specialties
6Manufactured by dsm-firmenich, Distributed by LBB Specialties
7Manufactured by Provital

Formulation Instructions:

  1. Add water to main vessel and mix with moderate agitation.
  2. Heat to 75°C, adding rest of Phase A at 45-50°C.
  3. Premix Phase B in a side vessel and heat to 75°C.
  4. When both phases are at 75°C, slowly pour Phase B into Phase A.
  5. Homogenize with GP head for 4 minutes at 60 Hz.
  6. Return to prop mixing and cool batch.
  7. Add Phase C at 65°C. Add Phase D at 50°C. Add Phase E at 35°C.
  8. Continue mixing until batch reaches 25°C.
This information and all further technical advice is based on our present knowledge and experience. However, it implies no liability, or other legal responsibility on our part, including with regard to existing third party intellectual property rights, especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the legal sense is intended or implied. We reserve the right to make any changes according to technological progress or further developments.